A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Retrospective analysis sought to determine the effectiveness, cost, and impact on postoperative opioid use for the 2 formulations when used in a perioperative pain management regimen.
[Cancer Management and Research] Retrospective review sought to determine how residual tumor diameter and number of cycles of adjuvant chemotherapy after surgery influenced prognosis for patients with OCCC.
Most study authors at the 2019 Society of Gynecologic Oncology Annual Meeting failed to disclose industry relationships, a study found.
Results of a large cohort study investigated sources of iatrogenic and noniatrogenic injuries in women coping with a potential diagnosis of cervical cancer.
The FDA approved FoundationOne CDx as a companion diagnostic for treatment selection of alpelisib for breast cancer, rucaparib for some gynecologic cancers, and alectinib for lung cancer.
